Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3, Open-label Trial to Evaluate Safety, Pharmacokinetics, and Efficacy of Benralizumab in Children With Eosinophilic Diseases (CLIPS)

NCT06512883 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06512883
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06512883 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3, Open-label Trial to Evaluate Safety, Pharmacokinetics, and Efficacy of Benralizumab in Children With Eosinophilic Diseases (CLIPS)
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Recruiting
Start date
April 17, 2025
Completion date
May 14, 2029
Enrollment
14 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

eosinophilic granulomatosis with polyangiitis (egpa), hypereosinophilia syndrome (hes)